- Home
- GLRE vs BNTC Comparison
GLRE vs BNTC Comparison
Compare GLRE & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLRE | BNTC |
|---|---|---|
| Founded | 2004 | 1995 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.5M | 411.4M |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GLRE | BNTC |
|---|---|---|
| Price | $17.39 | $12.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $27.67 |
| AVG Volume (30 Days) | ★ 163.9K | 96.3K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 75.00 | ★ 80.94 |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $729,777,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.86 | ★ N/A |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $11.57 | $9.85 |
| 52 Week High | $19.39 | $17.15 |
Technical Indicators
Market Signals| Indicator | GLRE | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 42.90 | 47.10 |
| Support Level | $12.46 | $11.40 |
| Resistance Level | $19.39 | $13.27 |
| Average True Range (ATR) | 0.61 | 0.65 |
| MACD | -0.19 | -0.10 |
| Stochastic Oscillator | 22.54 | 32.31 |
Price Performance
Historical ComparisonAbout GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.